Synosia gets rights to Novartis Pharma's rufinamide
Synosia Therapeutics (formerly Synosis Therapeutics; focused on CNS disorders) has licensed exclusive global rights--excluding Japan--to Novartis Pharma's rufinamide for anxiety disorders and bipolar mood disorders. Synosia plans to begin Phase II studies later this year.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com